Business Standard

A COMMERCIAL FEATURE

What's this ?

Commercial Feature is a Business Standard Digital Marketing Initiative.

The Editorial/Content team at Business Standard has not contributed to writing or editing these articles.

For further information, please write to assist@bsmail.in

Glenmark starts clinical trial for biosimilar used to treat allergic asthma

The reference product for this biosimilar is omalizumab, sold under the brand name Xolair

BS B2B Bureau  |  Mumbai 

The US Food and Drug Administration (FDA) has cleared Pharmaceuticals’ investigational new drug (IND) application to initiate a first-in-human study of GBR 310, a proposed biosimilar, which will assess its pharmacokinetics in comparison to (omalizumab) in healthy adult volunteers between 18-65 years of age.

“This marks the second IND activation in 2017 for our growing respiratory portfolio. In the seven years since the US approval process for medicines was signed into law, there have been few candidates successfully developed. GBR 310 has the potential to be among the first candidates to be submitted for approval for a respiratory or allergic disease,” said Kurt Stoeckli, president and chief scientific officer at Pharmaceuticals.

GBR 310 is a recombinant DNA-derived humanised immunoglobulin G1 kappa monoclonal antibody. Its current proposed indication is for the treatment of allergic and chronic idiopathic urticaria. The reference product for GBR 310 is omalizumab, available under the brand name

According to sales data for the 12-month period ending February 2017, annual sales of 150 mg injection was approximately $1.7 billion in the US.

is one of the most common diseases in children and affects more than 18 million people older than 18 in the US. Allergic is unique because it is triggered by exposure to year-round allergens like pet dander and dust mites. Allergies trigger attacks in 60-90 percent of children with and in approximately 50 percent of adults.

Urticaria is a common skin disease that presents as spontaneously recurring hives or welts. It occurs across all age groups and about one percent of the population suffers from a chronic form of the disease. Among this group, 70 percent of people report symptoms that last for more than one year and 14 percent report symptoms that last for more than five years.

RECOMMENDED FOR YOU

Glenmark starts clinical trial for biosimilar used to treat allergic asthma

The reference product for this biosimilar is omalizumab, sold under the brand name Xolair

The reference product for this biosimilar is omalizumab, sold under the brand name Xolair
The US Food and Drug Administration (FDA) has cleared Pharmaceuticals’ investigational new drug (IND) application to initiate a first-in-human study of GBR 310, a proposed biosimilar, which will assess its pharmacokinetics in comparison to (omalizumab) in healthy adult volunteers between 18-65 years of age.

“This marks the second IND activation in 2017 for our growing respiratory portfolio. In the seven years since the US approval process for medicines was signed into law, there have been few candidates successfully developed. GBR 310 has the potential to be among the first candidates to be submitted for approval for a respiratory or allergic disease,” said Kurt Stoeckli, president and chief scientific officer at Pharmaceuticals.

GBR 310 is a recombinant DNA-derived humanised immunoglobulin G1 kappa monoclonal antibody. Its current proposed indication is for the treatment of allergic and chronic idiopathic urticaria. The reference product for GBR 310 is omalizumab, available under the brand name

According to sales data for the 12-month period ending February 2017, annual sales of 150 mg injection was approximately $1.7 billion in the US.

is one of the most common diseases in children and affects more than 18 million people older than 18 in the US. Allergic is unique because it is triggered by exposure to year-round allergens like pet dander and dust mites. Allergies trigger attacks in 60-90 percent of children with and in approximately 50 percent of adults.

Urticaria is a common skin disease that presents as spontaneously recurring hives or welts. It occurs across all age groups and about one percent of the population suffers from a chronic form of the disease. Among this group, 70 percent of people report symptoms that last for more than one year and 14 percent report symptoms that last for more than five years.

image
Business Standard
177 22

Glenmark starts clinical trial for biosimilar used to treat allergic asthma

The reference product for this biosimilar is omalizumab, sold under the brand name Xolair

The US Food and Drug Administration (FDA) has cleared Pharmaceuticals’ investigational new drug (IND) application to initiate a first-in-human study of GBR 310, a proposed biosimilar, which will assess its pharmacokinetics in comparison to (omalizumab) in healthy adult volunteers between 18-65 years of age.

“This marks the second IND activation in 2017 for our growing respiratory portfolio. In the seven years since the US approval process for medicines was signed into law, there have been few candidates successfully developed. GBR 310 has the potential to be among the first candidates to be submitted for approval for a respiratory or allergic disease,” said Kurt Stoeckli, president and chief scientific officer at Pharmaceuticals.

GBR 310 is a recombinant DNA-derived humanised immunoglobulin G1 kappa monoclonal antibody. Its current proposed indication is for the treatment of allergic and chronic idiopathic urticaria. The reference product for GBR 310 is omalizumab, available under the brand name

According to sales data for the 12-month period ending February 2017, annual sales of 150 mg injection was approximately $1.7 billion in the US.

is one of the most common diseases in children and affects more than 18 million people older than 18 in the US. Allergic is unique because it is triggered by exposure to year-round allergens like pet dander and dust mites. Allergies trigger attacks in 60-90 percent of children with and in approximately 50 percent of adults.

Urticaria is a common skin disease that presents as spontaneously recurring hives or welts. It occurs across all age groups and about one percent of the population suffers from a chronic form of the disease. Among this group, 70 percent of people report symptoms that last for more than one year and 14 percent report symptoms that last for more than five years.

image
Business Standard
177 22